Fenglei Huang, PhD, FCP, is a Director in Clinical Pharmacology at Boehringer Ingelheim, where he also chairs the Drug–Drug Interaction Expert Group. He received his Ph.D. in Pharmaceutical Sciences from the University of Florida and is an elected Fellow of the American College of Clinical Pharmacology. His research focuses on drug–drug interactions, translational pharmacokinetics/pharmacodynamics (PK/PD), and pediatric drug development across multiple therapeutic areas, including inflammation, cardiovascular and metabolic diseases, central nervous system disorders, and infectious diseases. He is an active member of both the American Association of Pharmaceutical Scientists and the American College of Clinical Pharmacology, where he has contributed to several committees, including the Annual Meeting Planning Committee, Publications Committee, and Credentials Committee. He has made significant contributions to the field, co-authoring over 40 peer-reviewed publications and presenting at more than 70 national and international conferences. In addition, He serves on the editorial boards of multiple international journals in clinical pharmacology and related biomedical sciences.